Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Pettenati

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Bioengineering (Basel, Switzerland)|July 27, 2024
In Vitro Generation of Haploid Germ Cells from Human XY and XXY Immature Testes in a 3D Organoid SystemGuillermo Galdon, Nima Pourhabibi Zarandi, Nicholas A Deebel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
International Journal of Oncology|July 19, 2008
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experienceKrzysztof Mrózek, Andrew J Carroll, Kati Maharry, et al.
Case Reports in Nephrology|May 16, 2015
Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donorAmudha Palanisamy, Paul Persad, Patrick P Koty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Genes, Chromosomes & Cancer|April 14, 2007
Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemiaNyla A Heerema, Susana C Raimondi, James R Anderson, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Bioengineering (Basel, Switzerland)|July 27, 2024
In Vitro Generation of Haploid Germ Cells from Human XY and XXY Immature Testes in a 3D Organoid SystemGuillermo Galdon, Nima Pourhabibi Zarandi, Nicholas A Deebel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|March 9, 2006
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Sherif S Farag, Kellie J Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
International Journal of Oncology|July 19, 2008
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experienceKrzysztof Mrózek, Andrew J Carroll, Kati Maharry, et al.
Case Reports in Nephrology|May 16, 2015
Donor-derived myeloid sarcoma in two kidney transplant recipients from a single donorAmudha Palanisamy, Paul Persad, Patrick P Koty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.
Genes, Chromosomes & Cancer|April 14, 2007
Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemiaNyla A Heerema, Susana C Raimondi, James R Anderson, et al.
Blood|October 24, 2002
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)John C Byrd, Krzysztof Mrózek, Richard K Dodge, et al.
Pageof 5